mouse monoclonal anti rad50  (Novus Biologicals)

Journal: NPJ Breast Cancer

Article Title: Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

doi: 10.1038/s41523-021-00350-5

Figure Lengend Snippet: a Western blot showing MRE11, RAD50 and NBS1 protein expression in a panel of breast cancer cell lines. All blots derive from the same experiment and they were processed in parallel. b Photomicrographs showing immunohistochemical staining of MRE11, RAD50 and NBS1 in breast cancers. c Correlation Matrix showing the correlation between levels of MRE11, NBS1 and RAD50 protein expressions and other DNA repair biomarkers. Blue colour refers to positive (+) correlation, while the red colour reflects negative (−) correlations. The size of the circles and intensity of the colour propionate to the correlation coefficient. The image was generated using RStudio software. Red arrow = proteins investigated in the current study i.e. MRE11, RAD50 and NBS1.

Article Snippet: A further set of slides were incubated for 18 h at 4 °C with the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a dilution of 1:100.

Techniques: Western Blot, Expressing, Immunohistochemical staining, Staining, Generated, Software

Journal: NPJ Breast Cancer

Article Title: Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

doi: 10.1038/s41523-021-00350-5

Figure Lengend Snippet: MRN complex protein expression and clinicopathological features in breast cancer.

Article Snippet: A further set of slides were incubated for 18 h at 4 °C with the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a dilution of 1:100.

Techniques: Expressing, Over Expression

Journal: NPJ Breast Cancer

Article Title: Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

doi: 10.1038/s41523-021-00350-5

Figure Lengend Snippet: a Kaplan–Meier curve for MRE11 nuclear protein expression and breast cancer-specific survival (BCSS) in the whole cohort. b Kaplan–-Meier curve for MRE11 nuclear protein expression and BCSS in ER+ cohort. c Kaplan–Meier curve for MRE11 nuclear protein expression and BCSS in ER− cohort. d Kaplan–Meier curve for RAD50 nuclear protein expression and BCSS in the whole cohort. e Kaplan–Meier curve for RAD50 nuclear protein expression and BCSS in ER+ cohort. f Kaplan–Meier curve for RAD50 nuclear protein expression and BCSS in ER− cohort. g Kaplan–Meier curve for NBS1 nuclear protein expression and BCSS in the whole cohort. h Kaplan–Meier curve for NBS1 nuclear protein expression and BCSS in ER+ cohort. i Kaplan–Meier curve for NBS1 nuclear protein expression and BCSS in ER− cohort.

Article Snippet: A further set of slides were incubated for 18 h at 4 °C with the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a dilution of 1:100.

Techniques: Expressing

Journal: NPJ Breast Cancer

Article Title: Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

doi: 10.1038/s41523-021-00350-5

Figure Lengend Snippet: a Kaplan–-Meier curve for RAD50 mRNA expression and breast cancer-specific survival (BCSS) in the whole cohort. b Kaplan–Meier curve for RAD50 mRNA expression and BCSS in ER+ cohort. c Kaplan–Meier curve for RAD50 mRNA expression and BCSS in ER− cohort. d Kaplan–Meier curve for has-miR-99b expression and BCSS in the whole cohort. e Kaplan–Meier curve for has-miR-99b expression and BCSS in ER+ cohort. f Kaplan–Meier curves for has-miR-99b expression and BCSS in ER− cohort. g Kaplan–Meier curves for has-miR-494 expression and BCSS in the whole cohort. h Kaplan–Meier curve for has-miR-494 expression and BCSS in ER+ cohort. i Kaplan–Meier curve for has-miR-494 expression and BCSS in ER− cohort.

Article Snippet: A further set of slides were incubated for 18 h at 4 °C with the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a dilution of 1:100.

Techniques: Expressing

Journal: NPJ Breast Cancer

Article Title: Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

doi: 10.1038/s41523-021-00350-5

Figure Lengend Snippet: Differentially expressed genes (DEGs) were identified using RNAseq data from the TCGA-BRCA cohort dichotomized on the basis of low (quartile 1) versus high (quartile 4) expression of MRE11 ( a ) , RAD50 ( b ) and NBN/NBS1 ( c ). We next identified DEGs that were low (77 genes) or higher (545 genes) in patients with lower expression of MRN components ( d – f ) and identified enriched KEGG pathways ( d , e ). Pathways related to mitochondrial dysfunction were associated with reduced MRN expression ( f ).

Article Snippet: A further set of slides were incubated for 18 h at 4 °C with the primary mouse monoclonal anti-RAD50 antibody (Ab489, Abcam), at a dilution of 1:100.

Techniques: Expressing

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Quantitative proteomic study of mitoxantrone-resistant NCI-H460 cell-xenograft tumors

doi:

Figure Lengend Snippet: Identification of differentially expressed proteins in mitoxantrone-resistant (M) and wild tumors NCI-H460 (N) cells xenografts tumors using LC-MS/MS

Article Snippet: The membrane was incubated in fresh blocking buffer (0.1% Tween 20 in Tris-buffered saline, pH 7.4, containing 5% non-fat dried milk) at room temperature for 1 hour and then probed with monoclonal mouse anti-RAD50 antibody (Abcam, Cambridge, UK) and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Zhongshan Gold Bridge Biotechnology Co. Ltd, China) in blocking buffer at 4°C overnight.

Techniques:

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Quantitative proteomic study of mitoxantrone-resistant NCI-H460 cell-xenograft tumors

doi:

Figure Lengend Snippet: Western blotting of RAD50 expression in vivo xenograft tumors. The band intensity shows that mitoxantrone-resistant cells xenograft results in upregulation of RAD50 compared with wild NCI-H460 cells xenograft. Data are means ± SD of the results from three independent experiments, **P < 0.01.

Article Snippet: The membrane was incubated in fresh blocking buffer (0.1% Tween 20 in Tris-buffered saline, pH 7.4, containing 5% non-fat dried milk) at room temperature for 1 hour and then probed with monoclonal mouse anti-RAD50 antibody (Abcam, Cambridge, UK) and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Zhongshan Gold Bridge Biotechnology Co. Ltd, China) in blocking buffer at 4°C overnight.

Techniques: Western Blot, Expressing, In Vivo

Journal: Oncology Letters

Article Title: Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo

doi: 10.3892/ol.2017.6602

Figure Lengend Snippet: Effects of CDHP and CDDP on the expression of DNA double strand break repair proteins in vitro . (A) Western blotting was performed to detect the expression levels of DNA double strand break repair proteins in SAS and HSC2 cells following CDDP and/or CDHP treatment. (B and C) CDDP and CDHP combination treatment reduced the expression of Ku70, Ku80, DNA-PKcs, Rad50, XRCC, XLF and Rad51 compared with that of CDDP or CDHP treatment alone, or the expression observed in the untreated control. Error bars represent the standard deviation of the mean of 3 independent experiments. *P<0.05 compared with the control (Mann-Whitney's U test). a, Untreated Control; b, CDHP 10 µg/ml; c, CDDP 1.0 µg/ml; d, CDDP+CDHP; CDHP, 5-chloro-2,4-dihydroxypyridine; CDDP, cisplatin; DNA-PKcs, DNA-dependent-protein kinase catalytic subunit; XRCC4, X-ray repair cross complementing protein 4; XLF, XRCC4-like factor.

Article Snippet: Following blocking the membranes at room temperature for 30 min, the membranes were incubated with anti-Ku70 mouse monoclonal antibody (dilution, 1:250; no. sc-5309; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-Ku80 rabbit polyclonal antibody (dilution, 1:500; no. 2753; Cell Signaling Technology, Danvers, MA, USA), anti-DNA-dependent-protein kinase catalytic subunit (DNA-PKcs) mouse monoclonal antibody (dilution, 1:500; no. sc-9051; Santa Cruz Biotechnology, Inc.), anti-Rad50 mouse monoclonal antibody (dilution, 1:200; no. sc-56209; Santa Cruz Biotechnology, Inc.), anti-X-ray repair cross complementing protein 4 (XRCC4) rabbit polyclonal antibody (dilution, 1:500; no. ab12069; Abcam, Cambridge, UK), anti-XRCC4-like factor (XLF) rabbit polyclonal antibody (dilution, 1:250; no. ab33499; Abcam), anti-Rad51 rabbit polyclonal antibody (dilution, 1:500; no. sc-8349; Santa Cruz Biotechnology, Inc.), or anti-α-tubulin mouse monoclonal antibody (dilution, 1:500; no. sc-5286; Santa Cruz Biotechnology, Inc.) at 4°C overnight.

Techniques: Expressing, In Vitro, Western Blot, Control, Standard Deviation, MANN-WHITNEY

Journal: Oncology Letters

Article Title: Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo

doi: 10.3892/ol.2017.6602

Figure Lengend Snippet: DNA double strand break repair protein expression levels in vivo . Immunohistochemical staining was performed to investigate the underlying mechanisms of the antitumor effects of CDDP and CDHP combination therapy. CDDP and CDHP combination therapy reduced the expression of Ku70, Ku80, DNA-PKcs, Rad50 and Rad51 in HSC2 tumors. Percentage of positively stained cells is described in each figure. Magnification, ×200. CDHP, 5-chloro-2,4-dihydroxypyridine; CDDP, cisplatin; DNA-PKcs, DNA-dependent-protein kinase catalytic subunit; XRCC4, X-ray repair cross complementing protein 4; XLF, XRCC4-like factor; PCNA, proliferating cell nuclear antigen.

Article Snippet: Following blocking the membranes at room temperature for 30 min, the membranes were incubated with anti-Ku70 mouse monoclonal antibody (dilution, 1:250; no. sc-5309; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-Ku80 rabbit polyclonal antibody (dilution, 1:500; no. 2753; Cell Signaling Technology, Danvers, MA, USA), anti-DNA-dependent-protein kinase catalytic subunit (DNA-PKcs) mouse monoclonal antibody (dilution, 1:500; no. sc-9051; Santa Cruz Biotechnology, Inc.), anti-Rad50 mouse monoclonal antibody (dilution, 1:200; no. sc-56209; Santa Cruz Biotechnology, Inc.), anti-X-ray repair cross complementing protein 4 (XRCC4) rabbit polyclonal antibody (dilution, 1:500; no. ab12069; Abcam, Cambridge, UK), anti-XRCC4-like factor (XLF) rabbit polyclonal antibody (dilution, 1:250; no. ab33499; Abcam), anti-Rad51 rabbit polyclonal antibody (dilution, 1:500; no. sc-8349; Santa Cruz Biotechnology, Inc.), or anti-α-tubulin mouse monoclonal antibody (dilution, 1:500; no. sc-5286; Santa Cruz Biotechnology, Inc.) at 4°C overnight.

Techniques: Expressing, In Vivo, Immunohistochemical staining, Staining

Journal: Cell Systems

Article Title: Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling

doi: 10.1016/j.cels.2016.11.013

Figure Lengend Snippet:

Article Snippet: Mouse monoclonal anti-Rad50 (clone 13B3/2C6) , Millipore , Cat#05-525; RRID: AB_309782.

Techniques: Transduction, Recombinant, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Software, Inhibition, Modification